3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
9
Phase 3
3
Phase 1/2
3
Phase NA
2
Phase 2/3
2
Phase 1
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
5
CNS
2
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Interventions
Temozolomide
11
Lomustine
6
Radiotherapy
4
Magnetic Resonance Spectroscopy
3
Etoposide
3
Carboplatin
3
Bevacizumab
3
vocimagene amiretrorepvec
2
Vincristine
2
Radiation
2
Gefitinib
2
veliparib
1
trofosfamide
1
trametinib
1
tozuleristide
1
tinostamustine
1
regorafenib
1
omburtamab I-131
1
entrectinib
1
dabrafenib
1
cobimetinib
1
carbon-11 acetate
1
capmatinib
1
antisecretory factor
1
alectinib
1
Vorinostat
1
Vemurafenib
1
Thiotepa
1
Sunitinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Gefitinib
×
CNS
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled
NCT02338011
2015-01-26
EGFR
Shanghai Chest Hospital
Phase 2/3
Unknown
210 enrolled